Compare Amylx Pharmaceuticals Inc (AMLX) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Crown Castle International Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $17.65 (market cap $1.98B), while Crown Castle International Corp trades at $79.99 (market cap $34.77B). The key difference: Crown Castle International Corp is far larger — about 17.6× Amylx Pharmaceuticals Inc's market cap, and Crown Castle International Corp pays a 5.34% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CCI | |
|---|---|---|
Market Cap | $1.98B | $34.77B |
Sector | Health | Real Estate |
52-Week High | $18.70 | $113.91 |
52-Week Low | $7.64 | $74.92 |
Enterprise Value | $1.70B | $64.59B |
Dividend Yield | — | 5.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Crown Castle (CCI) trades at $79.66, up 3.89% today, but remains in a bearish technical trend with weak moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, while revenue declined to $4.26B in 2025. Analyst consensus is divided with a $97.33 price target, and the stock offers a 5.55% dividend yield. Recent news highlights strategic shifts to a pure-play tower focus amid leadership changes.
Outlook is cautious due to high debt levels and competitive pressures, but long-term value exists if operational improvements materialize. Key risks include interest rate sensitivity and execution challenges. Investors should weigh the dividend appeal against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
